FDA Maps New Paths for Rare-Disease Drug Evidence, Keeps Bar High

Overview

• The FDA issued new rare-disease guidance this year, including the Rare Disease Evidence Pathway, the Plausible Mechanism Pathway, and advice on innovative designs for cellular and gene therapy trials in small populations.
• The agency renewed the Rare Pediatric Disease Designation and Priority Review Voucher programs to sustain incentives for developers.
• Despite these updates, several drug applications have been turned down over disagreements about surrogate endpoints and study design.
• The documents signal conditional openness to such endpoints and designs, with acceptance limited to defined scenarios and case-by-case judgments.
• Industry editors Abigail Beaney, Robert Barrie, and Frankie Fattorini examined the implications in a Feb. 27 podcast released ahead of Rare Disease Day on Feb. 28.